Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market
Company introduces bioequivalent version of Edarbi for hypertension treatment following U.S. FDA approval; product recorded annual U.S. sales of USD 53.5 million
Expanded indication makes Stelo the first FDA-cleared OTC CGM for children aged two years and older with diabetes or prediabetes
The approval clears the company to market a generic version that is therapeutically equivalent to Retin-A Cream
Pharmaceutical R&D veteran brings over 20 years of expertise in formulation development, ANDA filings, and regulated-market product innovation to strengthen MSN Laboratories’ global growth ambitions
Company may qualify for 180-day generic exclusivity as sole first applicant for Bayer’s Vitrakvi capsules in the U.S.
The landmark legislation has laid the foundation for a skilled, regulated and globally competitive Allied and Healthcare Professional workforce, reshaping healthcare education and delivery across India
Researchers say the results point to a potential shift in how obesity is treated—as a central disease driving multiple conditions, rather than a collection of separate problems
The agreement underscores Roche’s commitment to advancing innovative therapies for blood cancers and other serious diseases
The approved product is therapeutically equivalent to Haldol tablets of Ortho McNeil Pharmaceutical
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
